Possible role of metformin as an antidepressant in diabetes
Journal of Affective Disorders · 2024
DOI: 10.1016/j.jad.2024.01.228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Adriana Pedreañez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cátedra de Inmunología, Escuela de Bioanálisis, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: Universidad del Zulia.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE: Metformin (MET) is a drug used in the treatment of type 2 diabetes due to its insulin receptor sensitizing properties and anti-hepatic gluconeogenesis effect. One of the comorbidities in diabetes is the depression. This review aimed at summarizing the results of the available MET, depression and diabetes studies to clarify the possible role of MET in the depression during diabetes. METHODS: A bibliographic search on PubMed, Embase, PsycINFO, Web of Science, Cochrane Central for studies referring to MET, depression and diabetes. RESULTS: Several studies have associated depression to the chronic inflammation that characterizes diabetes. Additionally MET is an anti-inflammatory molecule that generally acts by activating AMPK and inhibiting the NF-kB factor. In the context of diabetes, MET can act directly as an anti-inflammatory drug as well as inhibiting other pro-inflammatory molecules. In this regard, MET may inhibit the pro-inflammatory effects of angiotensin II. By facilitating the action of insulin and reducing hepatic gluconeogenesis, MET reduces circulating glucose levels, decreasing the formation of advanced glycation end products and therefore inflammation. During diabetes, the gut microbiota and the permeability of the intestinal barrier are altered, causing high levels of circulating lipopolysaccharides (LPS), which induce inflammation. MET can normalize the microbiota and the intestinal barrier permeability reducing the levels of LPS and inflammation. Clinical and experimental studies show the anti-depressant effect of MET mediated by different mechanisms both at the peripheral level and in the central nervous system. CONCLUSION: Therefore, MET as an anti-inflammatory drug can decrease symptoms of depression and represents a therapeutic approach to improve the psychological state of patients with diabetes. Additionally, insulin also has an anti-inflammatory effect that could act together with MET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cátedra de Inmunología, Escuela de Bioanálisis, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela.
- Instituto de Investigaciones Clínicas "Dr. Américo Negrette", Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela.
- Instituto de Investigaciones Clínicas "Dr. Américo Negrette", Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela; Servicio de Microscopia Electrónica del Centro Nacional de Biotecnología (CNB-CSIC) Madrid…
- Instituto de Investigaciones Clínicas "Dr. Américo Negrette", Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela. Electronic address: mosquera99ve@yahoo.com.
Förderung
- Universidad del Zulia
Zitieren
APA
Pedreañez, A., Carrero, Y., Vargas, R., Hernandez-Fonseca, J. P., & Mosquera-Sulbaran, J. (2024). Possible role of metformin as an antidepressant in diabetes. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.01.228
Vancouver
Pedreañez A, Carrero Y, Vargas R, Hernandez-Fonseca JP, Mosquera-Sulbaran J. Possible role of metformin as an antidepressant in diabetes. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.01.228
BibTeX
@article{Pedreaez2024,
author = {Pedreañez, Adriana and Carrero, Yenddy and Vargas, Renata and Hernandez-Fonseca, Juan P and Mosquera-Sulbaran, Jesús},
title = {Possible role of metformin as an antidepressant in diabetes},
journal = {Journal of Affective Disorders},
year = {2024},
doi = {10.1016/j.jad.2024.01.228}
}
EUVIMED